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OBJECTIVES: Herpes zoster has been widely described in the context of different systemic autoimmune diseases
but not dermatomyositis/polymyositis. Therefore, we analyzed the prevalence, risk factors and herpes zoster
outcomes in this population.
METHOD: A retrospective cohort study of herpes zoster infections in dermatomyositis/polymyositis patients was
performed. The patients were followed at a tertiary center from 1991 to 2012. For the control group, each
patient with herpes zoster was paired with two patients without herpes zoster. Patients were matched by
gender and the type of myositis, age at myositis onset and disease duration.
RESULTS: Of 230 patients, 24 (10.4%) had a histories of herpes zoster (19 with dermatomyositis and five with
polymyositis, two-thirds female). The mean age of the patients with herpes zoster was 44.6¡16.8 years. No
difference between the groups was found regarding cumulative clinical manifestations. Disease activity,
autoantibody, muscle and leukogram parameters were also comparable between the groups. No differences in
immunosuppressive (alone or in association with other immunosuppressive therapies) or glucocorticoid (current
use, medium dose and cumulative dose in the last two months) therapies were found between patients with and
without herpes zoster. However, a higher proportion of patients in the herpes zoster group received chloroquine
diphosphate compared to the control group. All of the patients received acyclovir; 58.3% of patients had
postherpetic neuralgia and no cases of recurrence were reported. Furthermore, individuals whowere taking high
prednisone doses at the time of the herpes zoster diagnosis had reduced levels of postherpetic neuralgia.
CONCLUSIONS: These data suggest that chloroquine diphosphate could predispose patients with dermatomyo-
sitis/polymyositis to developing herpes zoster, particularly women and dermatomyositis patients.
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& INTRODUCTION
Idiopathic inflammatory myopathies encompass a hetero-
geneous group of systemic autoimmune diseases, including
polymyositis (PM), which is characterized by symmetrical
proximal and progressive muscle weakness of the limbs and
dermatomyositis (DM), which, in addition to muscle
involvement, includes skin abnormalities, such as heliotrope
and Gottron’s papules (1,2).
Viral infections, such as herpes zoster (HZ), have
been increasingly reported in individuals with systemic
autoimmune diseases. Among patients with systemic lupus
erythematosus, for instance, there is an HZ prevalence of
4.5% (3) and an incidence of 6.4–58.7 events/1,000 patient-
years (3,4). Corticosteroids (3) and immunosuppressive
agents (4–6), disease activity (5–8) and the presence of
anti-Sm autoantibodies (8) number among the possible risk
factors for HZ in this population. The incidence of HZ in
rheumatoid arthritis is 9.96 cases/1,000 patient-years (9),
and the risk factors in this cohort include older age (.45
years old), the presence of cancer, chronic lung disease,
corticosteroid usage (10), exposure to immunosuppressive
(10) and immunobiological therapies (11) and immune
system dysregulation (12).
Through a few epidemiological studies, HZ in DM/PM
has been investigated within the context of other opportu-
nist infections or by examining a few myositis cases with
HZ (13–15). Thus, Fardet et al. (13) analyzed the incidence,
risk factors, and severity of HZ in 121 patients with DM.
However, these authors evaluated HZ and herpes simplex
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in DM patients with and without malignancy. Marie et al. (14)
assessed several opportunistic and severe infections in 279
patients with DM/PM for a period of 13 years, but they found
only three cases of HZ. Nagaoka et al. (15) analyzed the
incidence of HZ in 22 patients with DM/PM over a period of
10 years. Five patients had histories of this viral infection,
which predominantly occurred in the remission stage of the
disease, showing no relationship with drug therapies.
Due to the dearth of publications on the topic, the aim of
this study was to analyze the prevalence, risk factors and
outcomes of HZ in our cohort of DM/PM patients.
& MATERIALS AND METHODS
Study population, clinical assessment and data
collection. Between January 1991 and January 2012, 230
consecutive patients with DM or PM and who fulfilled at
least four of the five Bohan and Peter (2) criteria were
followed at a tertiary hospital. Twenty-four subjects (10.4%)
in this group had histories of HZ. Of the remaining patients
without HZ, a control group of 48 patients (two controls for
every HZ patient) was formed and matched by gender,
disease type (DM or PM), age at the onset of myositis and
disease duration. The study was approved by the local
Research Ethics Committee.
Demographics, drug therapy and clinical and laboratory
data were retrospectively obtained through a systematic
review of all patient medical records. Drug therapy and
laboratory data were based on the time of the DM/PM
diagnosis and the season in which the HZ event occurred,
while the clinical manifestations considered were those
presenting during the follow-up of these patients.
Constitutional symptoms, skin changes (e.g., heliotrope,
Gottron’s papules, ulcers, photosensitive, calcinosis, and
vasculitis), joint involvement (arthralgia and/or arthritis),
and gastrointestinal (dysphagia) and respiratory (dyspnea
on moderate exertion) manifestations were analyzed.
Creatine kinase (normal range 24–173 IU/L) and aldolase
(1.0–7.5 IU/L) were determined using an automated kinetic
assay. Leukocyte count, lactate dehydrogenase, alanine
aminotransferase and aspartate aminotransferase were also
assessed. The erythrocyte sedimentation rate and C-reactive
protein levels were evaluated using the Westergren
and nephelometry methods, respectively. Autoantibodies
against cellular components were determined with indirect
immunofluorescence using Hep-2 cells as the substrate.
Autoantibody anti-Jo-1 was determined using the Western
blotting method.
All of the patients were first started on corticosteroids
(prednisone 1 mg/kg/day, administered orally), which were
tapered gradually according to clinical and laboratory
stability. In cases of high disease severity (dysphagia with
risk of aspiration pneumonia, cutaneous vasculitis, or being
refractory to oral corticosteroids), intravenous corticosteroids
were administered (methyl prednisolone 1 g/day for three
consecutive days). The following drugs were used alone or in
combination for corticosteroid sparing: azathioprine (2–
3 mg/kg/day), methotrexate (20–25 mg/week), cyclospor-
ine (2–3 mg/kg/day), mycophenolate mofetil (2–3 g/day),
leflunomide (20 mg/day), cyclophosphamide (0.5–1.0 g/m2
of body surface), intravenous human immunoglobulin (1 g/
kg/day for two consecutive days) and chloroquine dipho-
sphate (3–4 mg/kg/day).
Herpes zoster information
HZ infection was clinically defined by the appearance of
the typical vesicular eruption distributed in a dermatome.
The potential complications of HZ, which were listed on the
protocol form, included postherpetic neuralgia (persistence
of pain for more than one month after the disappearance
of the rash) (16) and cutaneous dissemination (vesicular
lesions outside the primary and adjacent dermatomes) (17).
All of the lesions were initially evaluated by rheumatolo-
gists and then by dermatologists from our service.
The disease status at the time of the HZ diagnosis was
defined as (a) partial clinical response (evidence of disease
activity within the last 6 months of disease); (b) complete
clinical response (6-month continuous period with no
evidence of disease activity while still receiving myositis
therapy); and (c) clinical remission (6-month continuous
period with no evidence of disease activity and no myositis
therapy) (17). Disease activity was defined as an increase in
muscle enzyme sera levels, with clinical evidence of limb
muscle weakness at two consecutive medical evaluations.
Statistical analysis
Continuous variables are expressed as the means¡stan-
dard deviations (SDs), as medians with interquartile ranges
(IQRs), or as percentages for categorical variables. Student’s
t-test or the Mann-Whitney U-test for continuous variables
was employed to evaluate the differences between the DM/
PM groups. The 95% confidence intervals (95% CI) were
calculated using binomial distribution. All of the variables
that significantly differed statistically in the univariable
analysis (comparison between patients with and without
HZ episodes or with and without neurological sequelae)
were selected for adjustment. The sex- and age-adjusted
odds ratios (ORs) and 95% CIs were calculated using an
unconditional logistic model, and p,0.05 was considered
statistically significant.
& RESULTS
Demographic and clinical features of patients with
and without herpes zoster
Over a 21-year follow-up period, 24 (10.4%) of 230
patients had HZ (19 DM cases and 5 PM cases, 3.8:1), and
two-thirds were female. The clinical and demographic
features of these patients are shown in Table 1. In general,
these characteristics were comparable between the groups
with and without HZ, except for a higher prevalence of DM
in the group with HZ compared to the patients without HZ
(p= 0.046).
The mean age of the patients with HZ was 44.6¡16.8
years (range 21 to 84 years). Demographic and clinical
variables of the 24 patients in the HZ group were compared
with those of the 48 randomly selected and matched
patients without HZ, as shown in Table 2. No differences
were detected between the two groups regarding the
cumulative clinical manifestations (Table 2). Furthermore,
the two groups were comparable in terms of current disease
status, laboratory parameters (initial and current) and
autoantibodies (Table 3).
All of the HZ patients initially received intravenous
acyclovir (30 mg/kg/day).
There was no difference between DM/PM with and
without HZ with regard to glucocorticoid therapy (current
use, medium dose and cumulative dose over the two
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previous months). Similarly, immunosuppressive therapy
use was similar in both groups (Table 4). However, the
patients using chloroquine diphosphate had a 5.98-fold
(95% CI, 1.66–22.26) greater risk of developing HZ com-
pared to the patients who did not receive chloroquine
diphosphate treatment.
Clinical evaluation and dermatome locations of
herpes zoster
Table 5 shows the dermatome locations of HZ, as well as
the clinical evaluations. Six cases had simultaneous involve-
ment of two dermatomes. Neurological sequelae occurred in
14 (58.3%) of 24 patients, and no cases of HZ recurrence
were reported. The duration of the neurological symptoms
was 8.2¡4.4 years.
The demographics, disease status and clinical and
laboratory features were comparable in the patients with
and without postherpetic neuralgia. However, the latter
group used a higher prednisone dose at the time of the HZ
diagnosis (median 40 mg/day [range 5-70]) than the former
group (median 15 mg/day [range 0–40], p= 0.018, with OR
of 0.93 and 95% CI of 0.86–0.99).
& DISCUSSION
The present study identified chloroquine diphosphate
as the primary risk factor for HZ in DM/PM. In our
population, we noted a high HZ prevalence that predomi-
nantly affected women and individuals with DM.
An important aspect of this retrospective study’s design
was its large cohort of HZ cases and associated risk factors
in the patients with DM and PM, which are both considered
rare systemic autoimmune diseases. Additionally, the study
and control groups were matched by age because there is a
known HZ cluster disparity between young and elderly
subjects. Moreover, gender, disease type (DM or PM), age at
diagnosis and disease duration were also controlled for by
sample matching to avoid a confounding bias.
Despite enrolling large samples, many authors have
found few HZ cases in their DM/PM populations.
Table 1 - Comparison of the general demographic and clinical features of the dermatomyositis/polymyositis patients
with and without herpes zoster.
HZ (+) HZ (2) p-value
(n = 24) (n = 206)
DM:PM ratio 19:5 113:87 0.046
Sex at disease onset ¡ SD (years) 43.8¡16.8 42.2¡14.2 0.123
Gender - female (%) 7 (71) 157 (97) 1.000
Time between disease diagnosis and symptoms (IQR) (mo) 5.0 (2.0–9.0) 3.0 (2.0–6.0) 0.264
Cumulative clinical manifestations
Constitutional symptoms (%) 15 (63) 105 (51) 0.521
Bedrest (%) 3 (13) 55 (27) 0.212
Articular: arthralgia/arthritis (%) 12 (50) 88 (43) 0.521
Gastrointestinal tract: dysphagia (%) 8 (34) 74 (36) 1.000
Pulmonary: dyspnea (%) 5 (21) 56 (27) 0.766
DM: dermatomyositis; HZ: herpes zoster; IQR: interquartile range; PM: polymyositis; SD: standard deviation.
Table 2 - Demographic and clinical features of selected patients with dermatomyositis/polymyositis according to the
presence of herpes zoster.
HZ (+) HZ (2) p-value
(n= 24) (n = 48)
DM: PM ratio 19:5 38:10 1.000
Age at disease onset ¡ SD (years) 43.8¡16.8 44.1¡15.3 0.935
Gender - female (%) 7 (71) 14 (71) 1.000
Time between disease diagnosis and symptoms (IQR) (mo) 5.0 (2.0–9.0) 3.0 (3.0–8.5)* 0.855
Time between HZ and disease diagnosis (IQR) (mo) 13.0 (6.0–31.0) 9.5 (5.9–19.0) 0.190
Cumulative clinical manifestations
Constitutional symptoms (%) 15 (63) 24 (50) 0.393
Bedrest (%) 3 (13) 11 (23) 0.290
Cutaneous
Heliotrope (%) 19 (79) 33 (69) 0.158
Gottron’s papules (%) 19 (79) 34 (71) 1.000
Vasculitis (%) 6 (25) 6 (13) 0.325
Calcinosis (%) 3 (13) 1 (2) 0.140
Ulcers (%) 3 (13) 6 (13) 0.269
Photosensitive (%) 12 (50) 20 (42) 1.000
Articular: arthralgia/arthritis (%) 12 (50) 16 (33) 0.171
Gastrointestinal tract: dysphagia (%) 8 (34) 22 (46) 0.310
Pulmonary: dyspnea (%) 5 (21) 12 (25) 0.766
*Comparable period for patients who developed herpes zoster.
DM: dermatomyositis; HZ: herpes zoster; IQR: interquartile range; PM: polymyositis; SD: standard deviation.
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Notably, Marie et al. (14) identified only three individuals
with HZ in 279 cases and Yu et al. (18) detected two subjects
with HZ among 192 cases of DM/PM, whereas Fardet et al.
(13) found 16 HZ cases among 121 DM patients. In the
present study, we evaluated 24 (10.4%) HZ cases among 230
patients who were clinically diagnosed with DM/PM over a
21-year follow-up period. Therefore, a considerable number
of infected patients were identified in this population.
Based on other systemic autoimmune diseases, such as
systemic lupus erythematosus and rheumatoid arthritis, the
major risk factors for developing HZ include older age, use
of corticosteroids and immunosuppressive agents, disease
activity, female sex, cancer, lung disease and impaired
cellular immunity (3–12,19–21).
In our population, HZ predominantly affected adults
with a mean age of 44 years (range 21 to 84 years), with no
tendency toward affecting older individuals. Moreover, to
avoid analysis bias, individuals with neoplasias were
excluded.
In contrast with other systemic autoimmune diseases, in
which impaired cellular immunity is considered a risk
factor for HZ development (12), humoral immunity function
might be considered relevant in inflammatory myopathies
because the prevalence of HZ was higher in the DM patients
compared to the PM patients. From an immunopathological
standpoint, CD8 (+) lymphocyte and macrophage infiltra-
tions are primarily found in PM muscle fibers (22), whereas
in DM, B cells play important roles in the pathogenesis of
the disease through the presence of autoantibodies, immune
complex deposition in the dermoepidermal junction of skin
lesions and the presence of B cells in inflamed muscles and
perivascular areas (23,24). Additionally, deposition of
complement and immunoglobulin in the perifascicular
endothelium can lead to ischemia and muscle atrophy,
underlining the importance of humoral immunity (25).
Thus, disturbances in humoral immunity might increase HZ
reactivation, as we found a higher prevalence of HZ in the
DM patients compared to the PM patients.
Nagaoka et al. (15) analyzed five HZ cases among 22
DM/PM patients and noted that the infection affected more
patients without disease activity; they found no correlation
over time with corticosteroid use. Our results showed that
HZ prevalence was independent of disease status and
clinical and laboratory features, including cutaneous man-
ifestations. Moreover, daily and/or cumulative dosages of
corticosteroid and/or intravenous pulse methylpredniso-
lone did not increase the risk for HZ development in our
population. Likewise, using immunosuppressive therapy
(methotrexate, azathioprine, mycophenolate mofetil, leflu-
nomide and cyclophosphamide)—either alone or in combi-
nation—was not associated with HZ.
However, patients using chloroquine diphosphate had
a fivefold greater risk of developing HZ compared to
patients not receiving chloroquine diphosphate treatment.
Table 3 - Disease status and laboratory features of patients with dermatomyositis/polymyositis according to the
presence of herpes zoster.
HZ (+) HZ (2) p-value
(n= 24) (n = 48)
Disease status
Complete clinical response 2 (8) 6 (13) 0.596
Partial clinical response 20 (83) 37 (77) 0.538
Clinical remission 2 (8) 7 (15) 0.450
Laboratory features
Creatine kinase (U/L)
At diagnosis 761.1 (254.0–4300.0) 3031.0 (148.0–9015.0) 0.449
At HZ event 178.5 (82.5–672.0) 14.0 (10.5–60.8)* 0.304
Aldolase (U/L)
At diagnosis 14.0 (7.5–49.5) 14.0 (10.5–60.8) 0.583
At HZ event 6.3 (4.6–9.9) 5.6 (4.9–8.2)* 0.594
Aspartate aminotransferase (U/L)
At diagnosis 86.5 (42.0–238.0) 82.0 (39.0–184.0) 0.898
At HZ event 45.9¡46.5 51.9¡59.2* 0.641
Alanine aminotransferase (U/L)
At diagnosis 63.5 (32.0–120.0) 63.0 (29.0–177.0) 0.685
At HZ event 42.4¡36.4 64.5¡118.3* 0.241
Lactate dehydrogenase (U/L)
At diagnosis 639.0 (390.0–1506.0) 714.0 (456.0–1109.0) 0.605
At HZ event 813.0 (386.5–736.0) 576.0 (450.0–623.0)* 0.926
At HZ event
Leukocytes (mm3) 7689.9¡3662.7 7161.5¡3129.0* 0.550
Neutrophils (mm3) 5875.0¡3112.1 4874.3¡2,759.0* 0.193
Lymphocytes (mm3) 1554.2¡960.5 1523.6¡955.8* 0.900
C-reactive protein (mg/dL) 4.9 (1.5–14.7) 2.1 (1.0–9.3)* 0.080
ESR (mm/1st hour) 18.4¡12.2 21.4¡19.6* 0.448
Antinuclear factor (%) 15 (63) 28 (58) 0.734
Anti-Jo-1 antibody (%) 3 (13) 1 (2) 0.069
*Comparable period for patients who developed herpes zoster. Results expressed as the means ¡ standard deviation or as median (interquartile ratios).
ESR: erythrocyte sedimentation rate; HZ: herpes zoster; SD: standard deviation.
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Chloroquine diphosphate and its analogue, hydroxychlor-
oquine, are used to treat various rheumatic diseases, such
as rheumatoid arthritis, systemic lupus erythematosus,
sarcoidosis, dermatomyositis, Sjo¨gren’s syndrome, chronic
juvenile arthritis and psoriatic arthritis; these drugs offer
clinical benefits with acceptable safety profiles (26–29).
Further, these drugs have also been used to treat inflam-
matory myopathies, particularly for the cutaneous symp-
toms of DM (30–34).
Chloroquine might also have antiviral activity (35). As a
lysosomotropic weak base, it impairs the replication of some
viruses by reducing the efficiency of endosome-mediated
virus entry or by inhibiting low-pH–dependent proteases in
trans-Golgi vesicles (35). Its antiviral activity against the
human immunodeficiency virus (36) and the SARS corona-
virus has also been demonstrated (37,38). However,
chloroquine has also been shown to increase symptom
severity and mortality (e.g., following Semliki Forest virus
and encephalomyocarditis virus infection, as well as
increasing viral titers in various organs) (39). Our results
clearly showed that chloroquine was a risk factor for HZ
development in subjects with DM/PM, independent of
disease status, therapy and demographic features.
Regarding the clinical evaluation, at least half of our
patients had neurological sequelae. Six patients had
simultaneous involvement of two dermatomes, while no
cases of HZ recurrence were reported. Postherpetic neur-
algia can result in severe pain such that patients are often
unable to wear clothing that comes in contact with the
lesions or be exposed to wind because of high skin
sensitivity in regions such as the thorax and face. The
incidence of postherpetic neuralgia rises from 10% among
individuals of all ages to as high as 40% among those aged




1 Left dorsal area Yes
2 Nose, left lower limb (L5) No
3 Face, left lower limb (L5) No
4 Thoracic area, left upper limb No
5 Lower right limb (tibial nerve) Yes
6 Left dorsal (T11) Yes
7 Left upper limb Yes
8 Dorsal area Yes
9 Left upper limb Yes
10 Dorsal area No
11 Dorsal area No
12 Dorsal area, left lower limb Yes
13 Right dorsal area (T11) Yes
14 Left thoracic area Yes
15 Left thoracic area, abdomen Yes
16 Trigeminal nerve Yes
17 Right lower limb No
18 Gluteus (S1 and S2) No
19 Left thoracic area Yes
20 Left thoracic area Yes
21 Left lower limb (S1) No
22 Trunk No
23 Right thoracic area No
24 Left thoracic area (T4) Yes
HZ: herpes zoster.
Table 4 - Drug use features of patients with dermatomyositis/polymyositis according to the presence of herpes zoster.
HZ (+) HZ (2) p-value
(n= 24) (n = 48)
Corticosteroid
Using (%) 21 (87.5) 37 (77.1) 0.292
Mean¡SD (mg/day) 26.5¡20.0 30.3¡27.1 0.515
$20 mg/day 14 (58.3) 26 (54.2) 0.805
Cumulative dose* (g) 1.5¡1.2 1.5¡1.4 0.928
Immunosuppressives
Azathioprine (%) 12 (50.0) 18 (37.5) 0.310
Mean¡SD (mg/kg/day) 2.4¡0.2 2.4¡0.3 0.721
Methotrexate (%) 6 (25.0) 19 (39.6) 0.220
Mean¡SD (mg/week) 23.0¡2.7 22.5¡2.6 0.727
Cyclosporine (%) 1 (4.2) 1 (2.1) 0.612
Mean¡SD (mg/kg/day) 2.0 2.0 1.000
IVIG (%) 1 (4.2) 3 (6.3) 0.716
Mean¡SD (g/kg) 2.0 2.0 1.000
Leflunomide (%) 1 (4.2) 0 0.154
Mean¡SD (mg/day) 20.0 – –
Cyclophosphamide (%) 4 (4.2) 2 (2.1) 0.612
Mean¡SD (g/m2 body surface) 0.8¡0.2 0.7¡0.3 0.795
Mycophenolate mofetil (%) 1 (4.2) 0 0.154
Mean¡SD (g/day) 3.0 – –
Chloroquine diphosphate (%) 9 (37.5) 5 (10.4) 0.006
Mean¡SD (mg/day) 3.2¡0.2 3.3¡0.3 0.814
Corticosteroid + immunosuppressive (%)
Using (%) 17 (70.8) 31 (64.6) 0.592
Number of immunosuppressives
One (%) 16 (66.7) 28 (58.3) 0.494
Two (%) 1 (4.2) 9 (18.8) 0.154
Three (%) 1(4.2) 0 0.131
HZ: herpes zoster; IVIG: intravenous immunoglobulin; SD: standard deviation;
Cumulative dose: past two months.
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50 years and older (40). A large prospective study identified
four independent predictors of postherpetic neuralgia: older
age, severe, acute pain, severe rash and a shorter duration of
rash before consultation (41). Although controversial, short-
term use of corticosteroids can reduce the pain severity and
improve patient quality of life in the acute phase (42). Note
that high prednisone doses at the time of HZ diagnosis were
found to decrease the incidence of postherpetic neuralgia in
our patients.
In conclusion, our data showed a high prevalence of HZ
in the DM/PM population studied and confirmed that
chloroquine diphosphate is a risk factor for HZ develop-
ment in this population, particularly women and DM
patients. Further research is necessary to evaluate the
possible molecular mechanism underlying the higher HZ
prevalence in DM subjects compared to PM patient
populations.
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